A UK COST-UTILITY ANALYSIS OF FERRIC CARBOXYMALTOSE VERSUS FERRIC DERISOMALTOSE IN PATIENTS WITH IRON DEFICIENCY ANEMIA AND INFLAMMATORY BOWEL DISEASE: INCORPORATION OF FRACTURE DATA

被引：0
|
作者：
Zoller, H. [1 ]
Pammer, L. M. [1 ]
Nottmeier, M. [2 ]
Poehlmann, J. [3 ]
Pollock, R. F. [3 ]
机构：
[1] Med Univ Innsbruck, Innsbruck, Austria
[2] Pharmacosmos AS, Ballerup 84, Denmark
[3] Covalence Res Ltd, Harpenden, Herts, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE68
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [21] An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
    Richard F. Pollock
    Gorden Muduma
    Advances in Therapy, 2018, 35 : 2128 - 2137
  • [22] An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
    Pollock, Richard F.
    Muduma, Gorden
    ADVANCES IN THERAPY, 2018, 35 (12) : 2128 - 2137
  • [23] Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
    Pollock, Richard F.
    Muduma, Gorden
    ADVANCES IN THERAPY, 2019, 36 (08) : 1821 - 1825
  • [24] Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
    Richard F. Pollock
    Gorden Muduma
    Advances in Therapy, 2019, 36 : 1821 - 1825
  • [25] Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
    Ayşegül Aksan
    Axel Dignass
    Jürgen Stein
    Advances in Therapy, 2019, 36 : 1817 - 1820
  • [26] Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
    Aksan, Ayseguel
    Dignass, Axel
    Stein, Juergen
    ADVANCES IN THERAPY, 2019, 36 (08) : 1817 - 1820
  • [27] Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
    Eun-A Lim
    Hyun-Soon Sohn
    Haeyoung Lee
    Sang-Eun Choi
    Cost Effectiveness and Resource Allocation, 12
  • [28] Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea
    Lim, Eun-A
    Sohn, Hyun-Soon
    Lee, Haeyoung
    Choi, Sang-Eun
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2014, 12
  • [29] Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease
    Carman, Nicholas
    Muir, Richard
    Lewindon, Peter
    TRANSLATIONAL PEDIATRICS, 2019, 8 (01) : 28 - 34
  • [30] FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease
    Evstatiev, Rayko
    Marteau, Philippe
    Iqbal, Tariq
    Khalif, Igor L.
    Stein, Juergen
    Bokemeyer, Bernd
    Chopey, Ivan V.
    Gutzwiller, Florian S.
    Riopel, Lise
    Gasche, Christoph
    GASTROENTEROLOGY, 2011, 141 (03) : 846 - U558
12345